9,300 Shares in LeMaitre Vascular, Inc. $LMAT Bought by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,300 shares of the medical instruments supplier’s stock, valued at approximately $1,015,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its stake in LeMaitre Vascular by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock worth $131,547,000 after purchasing an additional 21,946 shares in the last quarter. First Trust Advisors LP grew its position in LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after buying an additional 111,193 shares in the last quarter. State Street Corp increased its stake in LeMaitre Vascular by 0.8% during the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock valued at $65,447,000 after buying an additional 6,130 shares during the period. Congress Asset Management Co. increased its stake in LeMaitre Vascular by 5.8% during the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock worth $51,351,000 after buying an additional 105,921 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. The trade was a 1.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the sale, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. The trade was a 56.13% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Price Performance

LMAT opened at $102.88 on Friday. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of 37.96, a PEG ratio of 2.86 and a beta of 0.52. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. LeMaitre Vascular, Inc. has a 1 year low of $79.00 and a 1 year high of $118.01. The stock has a fifty day moving average price of $98.79 and a 200 day moving average price of $97.19.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. The business had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Analysts forecast that LeMaitre Vascular, Inc. will post 3 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were paid a dividend of $0.25 per share. The ex-dividend date was Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 36.90%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Wells Fargo & Company raised their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday. Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research report on Tuesday, March 31st. Finally, Citizens Jmp upped their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and an average price target of $112.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.